vs
Side-by-side financial comparison of CHAMPIONS ONCOLOGY, INC. (CSBR) and Farmland Partners Inc. (FPI). Click either name above to swap in a different company.
Farmland Partners Inc. is the larger business by last-quarter revenue ($20.7M vs $15.0M, roughly 1.4× CHAMPIONS ONCOLOGY, INC.). Farmland Partners Inc. runs the higher net margin — 103.4% vs 1.8%, a 101.6% gap on every dollar of revenue. On growth, CHAMPIONS ONCOLOGY, INC. posted the faster year-over-year revenue change (11.5% vs -3.5%). Over the past eight quarters, Farmland Partners Inc.'s revenue compounded faster (31.4% CAGR vs 11.8%).
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
Farmland Industries was the largest agricultural cooperative in North America when it eventually sold all of its assets in 2002–04. During its 74-year history, Farmland served its farmer membership as a diversified, integrated organization, playing a significant role in agricultural markets both domestically and worldwide.
CSBR vs FPI — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.0M | $20.7M |
| Net Profit | $268.0K | $21.4M |
| Gross Margin | 51.7% | — |
| Operating Margin | 1.2% | — |
| Net Margin | 1.8% | 103.4% |
| Revenue YoY | 11.5% | -3.5% |
| Net Profit YoY | -63.2% | -63.5% |
| EPS (diluted) | $0.02 | $0.44 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.0M | $20.7M | ||
| Q3 25 | $14.0M | $11.3M | ||
| Q2 25 | $12.4M | $10.0M | ||
| Q1 25 | $17.0M | $10.3M | ||
| Q4 24 | $13.5M | $21.5M | ||
| Q3 24 | $14.1M | $13.3M | ||
| Q2 24 | $14.0M | $11.4M | ||
| Q1 24 | $12.0M | $12.0M |
| Q4 25 | $268.0K | $21.4M | ||
| Q3 25 | $-436.0K | $483.0K | ||
| Q2 25 | $-1.8M | $7.6M | ||
| Q1 25 | $4.5M | $2.0M | ||
| Q4 24 | $728.0K | $58.7M | ||
| Q3 24 | $1.3M | $1.8M | ||
| Q2 24 | $-109.0K | $-2.0M | ||
| Q1 24 | $-2.5M | $1.4M |
| Q4 25 | 51.7% | — | ||
| Q3 25 | 42.9% | — | ||
| Q2 25 | 41.1% | — | ||
| Q1 25 | 61.2% | — | ||
| Q4 24 | 44.9% | — | ||
| Q3 24 | 49.7% | — | ||
| Q2 24 | 48.2% | — | ||
| Q1 24 | 34.7% | — |
| Q4 25 | 1.2% | — | ||
| Q3 25 | -3.8% | 4.3% | ||
| Q2 25 | -16.2% | 78.2% | ||
| Q1 25 | 26.4% | 20.6% | ||
| Q4 24 | 5.4% | — | ||
| Q3 24 | 9.5% | 13.9% | ||
| Q2 24 | -1.9% | -17.9% | ||
| Q1 24 | -21.4% | 11.9% |
| Q4 25 | 1.8% | 103.4% | ||
| Q3 25 | -3.1% | 4.3% | ||
| Q2 25 | -14.9% | 76.3% | ||
| Q1 25 | 26.4% | 19.9% | ||
| Q4 24 | 5.4% | 273.6% | ||
| Q3 24 | 9.3% | 13.5% | ||
| Q2 24 | -0.8% | -17.5% | ||
| Q1 24 | -21.1% | 11.5% |
| Q4 25 | $0.02 | $0.44 | ||
| Q3 25 | $-0.03 | $0.00 | ||
| Q2 25 | $-0.12 | $0.14 | ||
| Q1 25 | $0.31 | $0.03 | ||
| Q4 24 | $0.05 | $1.09 | ||
| Q3 24 | $0.09 | $0.02 | ||
| Q2 24 | $-0.01 | $-0.06 | ||
| Q1 24 | $-0.19 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | — |
| Total DebtLower is stronger | — | $161.6M |
| Stockholders' EquityBook value | $4.2M | $467.4M |
| Total Assets | $30.2M | $719.1M |
| Debt / EquityLower = less leverage | — | 0.35× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.5M | — | ||
| Q3 25 | $10.3M | — | ||
| Q2 25 | $9.8M | — | ||
| Q1 25 | $3.2M | — | ||
| Q4 24 | $2.8M | — | ||
| Q3 24 | $2.9M | — | ||
| Q2 24 | $2.6M | — | ||
| Q1 24 | $4.5M | — |
| Q4 25 | — | $161.6M | ||
| Q3 25 | — | $170.4M | ||
| Q2 25 | — | $193.4M | ||
| Q1 25 | — | $202.6M | ||
| Q4 24 | — | $204.6M | ||
| Q3 24 | — | $394.0M | ||
| Q2 24 | — | $393.0M | ||
| Q1 24 | — | $383.0M |
| Q4 25 | $4.2M | $467.4M | ||
| Q3 25 | $3.5M | $457.3M | ||
| Q2 25 | $3.8M | $473.5M | ||
| Q1 25 | $5.5M | $492.2M | ||
| Q4 24 | $681.0K | $494.6M | ||
| Q3 24 | $-332.0K | $519.4M | ||
| Q2 24 | $-1.9M | $521.5M | ||
| Q1 24 | $-2.1M | $526.7M |
| Q4 25 | $30.2M | $719.1M | ||
| Q3 25 | $30.5M | $738.5M | ||
| Q2 25 | $32.3M | $776.7M | ||
| Q1 25 | $30.6M | $810.5M | ||
| Q4 24 | $25.2M | $869.6M | ||
| Q3 24 | $24.9M | $1.0B | ||
| Q2 24 | $26.1M | $1.0B | ||
| Q1 24 | $26.8M | $1.0B |
| Q4 25 | — | 0.35× | ||
| Q3 25 | — | 0.37× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | — | 0.41× | ||
| Q4 24 | — | 0.41× | ||
| Q3 24 | — | 0.76× | ||
| Q2 24 | — | 0.75× | ||
| Q1 24 | — | 0.73× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $17.4M |
| Free Cash FlowOCF − Capex | $-2.0M | — |
| FCF MarginFCF / Revenue | -13.1% | — |
| Capex IntensityCapex / Revenue | 1.6% | — |
| Cash ConversionOCF / Net Profit | -6.47× | 0.81× |
| TTM Free Cash FlowTrailing 4 quarters | $5.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.7M | $17.4M | ||
| Q3 25 | $600.0K | $-2.0M | ||
| Q2 25 | $6.9M | $-2.2M | ||
| Q1 25 | $490.0K | $6.4M | ||
| Q4 24 | $-283.0K | $16.1M | ||
| Q3 24 | $311.0K | $-4.3M | ||
| Q2 24 | $-1.8M | $-6.1M | ||
| Q1 24 | $-919.0K | $11.9M |
| Q4 25 | $-2.0M | — | ||
| Q3 25 | $554.0K | — | ||
| Q2 25 | $6.6M | — | ||
| Q1 25 | $448.0K | — | ||
| Q4 24 | $-377.0K | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-1.8M | — | ||
| Q1 24 | $-1.0M | — |
| Q4 25 | -13.1% | — | ||
| Q3 25 | 4.0% | — | ||
| Q2 25 | 53.5% | — | ||
| Q1 25 | 2.6% | — | ||
| Q4 24 | -2.8% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -13.0% | — | ||
| Q1 24 | -8.4% | — |
| Q4 25 | 1.6% | — | ||
| Q3 25 | 0.3% | — | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.7% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.8% | — |
| Q4 25 | -6.47× | 0.81× | ||
| Q3 25 | — | -4.04× | ||
| Q2 25 | — | -0.29× | ||
| Q1 25 | 0.11× | 3.12× | ||
| Q4 24 | -0.39× | 0.27× | ||
| Q3 24 | 0.24× | -2.39× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 8.66× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
FPI
Segment breakdown not available.
